Azithromycin: mechanisms of action and their relevance for clinical applications MJ Parnham, VE Haber, EJ Giamarellos-Bourboulis, G Perletti, ... Pharmacology & therapeutics 143 (2), 225-245, 2014 | 730 | 2014 |
Nrf2, the master regulator of anti-oxidative responses S Vomund, A Schäfer, MJ Parnham, B Brüne, A Von Knethen International journal of molecular sciences 18 (12), 2772, 2017 | 628 | 2017 |
Anti-inflammatory effects of macrolide antibiotics O Čulić, V Eraković, MJ Parnham European journal of pharmacology 429 (1-3), 209-229, 2001 | 493 | 2001 |
Ebselen: prospective therapy for cerebral ischaemia M Parnham, H Sies Expert opinion on investigational drugs 9 (3), 607-619, 2000 | 338 | 2000 |
Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects O Čulić, V Eraković, I Čepelak, K Barišić, K Brajša, Ž Ferenčić, R Galović, ... European journal of pharmacology 450 (3), 277-289, 2002 | 335 | 2002 |
The early research and development of ebselen MJ Parnham, H Sies Biochemical pharmacology 86 (9), 1248-1253, 2013 | 236 | 2013 |
Pharmacology of synthetic organic selenium compounds MJ Parnham, E Graf, VM Kolb, R Seth, S Sinha, RR Ruffolo, JP Hieble, ... Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des …, 1991 | 233 | 1991 |
Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions MJ Parnham, E Graf Biochemical pharmacology 36 (19), 3095-3102, 1987 | 230 | 1987 |
Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin M Bosnar, Z Kelneric, V Munic, V Erakovic, MJ Parnham Antimicrobial agents and chemotherapy 49 (6), 2372-2377, 2005 | 215 | 2005 |
Rosmarinic acid: a new inhibitor of complement C3-convertase with anti-inflammatory activity W Englberger, U Hadding, E Etschenberg, E Graf, S Leyck, J Winkelmann, ... International journal of immunopharmacology 10 (6), 729-737, 1988 | 197 | 1988 |
Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections MJ Parnham Current opinion in infectious diseases 18 (2), 125-131, 2005 | 192 | 2005 |
A novel biologically active seleno-organic compound—III: effects of PZ 51 (ebselen) on glutathione peroxidase and secretory activities of mouse macrophages MJ Parnham, S Kindt Biochemical pharmacology 33 (20), 3247-3250, 1984 | 180 | 1984 |
Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections H Sies, MJ Parnham Free Radical Biology and Medicine 156, 107-112, 2020 | 178 | 2020 |
THP-1 and human peripheral blood mononuclear cell-derived macrophages differ in their capacity to polarize in vitro H Shiratori, C Feinweber, S Luckhardt, B Linke, E Resch, G Geisslinger, ... Molecular immunology 88, 58-68, 2017 | 177 | 2017 |
Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression VI Tkalčević, S Čužić, K Brajša, B Mildner, A Bokulić, K Šitum, D Perović, ... European journal of pharmacology 570 (1-3), 212-221, 2007 | 173 | 2007 |
Ceramides as novel disease biomarkers J Kurz, MJ Parnham, G Geisslinger, S Schiffmann Trends in molecular medicine 25 (1), 20-32, 2019 | 170 | 2019 |
Prostaglandins and chronic inflammation IL Bonta, MJ Parnham Biochemical Pharmacology 27 (12), 1611-1623, 1978 | 170 | 1978 |
Pharmacokinetics of non-intravenous formulations of fentanyl J Lötsch, C Walter, MJ Parnham, BG Oertel, G Geisslinger Clinical pharmacokinetics 52, 23-36, 2013 | 168 | 2013 |
Toxicity screening of liposomes MJ Parnham, H Wetzig Chemistry and physics of lipids 64 (1-3), 263-274, 1993 | 166 | 1993 |
Benefit-risk assessment of the squeezed sap of the purple coneflower (Echinacea purpurea) for long-term oral immunostimulation MJ Parnham Phytomedicine 3 (1), 95-102, 1996 | 148 | 1996 |